Kepler Cheuvreux and Centile Partners have entered a strategic partnership in a bid to establish an enhanced presence in the listed derivatives market. The collaboration will bridge Kepler Cheuvreux’s ...

Kepler Cheuvreux downgraded Valerio Therapeutics shares from Hold to Reduce, significantly lowering the price target to EUR0.01 from EUR0.10. The downgrade follows the company's announcement of a ...

Kepler Cheuvreux downgraded Signify (SFFYF) to Reduce from Hold with a price target of EUR 18, down from EUR 25. The firm cites the company’s ...

Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH, a common and progressive chronic liver ...

Co SE (KCO:GR) with a Buy rating and a price target of EUR8.10. The firm's analysts highlight the company's strategic shift towards more promising opportunities in North America and the ...

PARIS--(BUSINESS WIRE)--Regulatory News: As regards the liquidity contract awarded by 74Software (Paris:74SW) to Kepler Cheuvreux, on December 31, 2024, the following means were listed in the ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener TipRanks is the ...

On Wednesday, Kepler Cheuvreux initiated coverage on Nexity (EPA:NEXI) SA (NXI:FP), a prominent player in the French real estate market, assigning a Hold rating to the company's shares.

Kepler Cheuvreux’s execution division KCx has expanded its execution access to the Middle East and Northern Africa (MENA). KCx’s expansion opens trading opportunities in the following countries: Dubai ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with ...